Short-course ART during primary HIV-1 infection (PHI) (Short Pulse Anti-Retroviral Therapy at Seroconversion Trial) also delayed the outcome of a primary end point, measured as CD4+ T-cell count less than 350 cells/μL or subsequent long-term ART initiation.[2]. Here, CD4 is linked to HIV-1 infection.